{"id":"leucovorin-lv","safety":{"commonSideEffects":[{"effect":"DIARRHOEA","drugRate":"71.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":834,"trialsReporting":2},{"effect":"NAUSEA","drugRate":"60.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":709,"trialsReporting":2},{"effect":"FATIGUE","drugRate":"42.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":502,"trialsReporting":2},{"effect":"Diarrhoea","drugRate":"52.5%","placeboRate":"","totalAtRisk":867,"totalAffected":455,"trialsReporting":3},{"effect":"Nausea","drugRate":"49.3%","placeboRate":"","totalAtRisk":867,"totalAffected":427,"trialsReporting":3},{"effect":"STOMATITIS ALL","drugRate":"63.8%","placeboRate":"","totalAtRisk":657,"totalAffected":419,"trialsReporting":1},{"effect":"NEUTROPENIA","drugRate":"35.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":411,"trialsReporting":2},{"effect":"RASH","drugRate":"33.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":396,"trialsReporting":2},{"effect":"Decreased appetite","drugRate":"42.9%","placeboRate":"","totalAtRisk":867,"totalAffected":372,"trialsReporting":3},{"effect":"Peripheral sensory neuropathy","drugRate":"42.4%","placeboRate":"","totalAtRisk":867,"totalAffected":368,"trialsReporting":3},{"effect":"VOMITING","drugRate":"30.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":357,"trialsReporting":2},{"effect":"Stomatitis","drugRate":"37.7%","placeboRate":"","totalAtRisk":867,"totalAffected":327,"trialsReporting":3},{"effect":"Dermatitis acneiform","drugRate":"63.0%","placeboRate":"","totalAtRisk":497,"totalAffected":313,"trialsReporting":2},{"effect":"ANOREXIA","drugRate":"26.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":312,"trialsReporting":2},{"effect":"Fatigue","drugRate":"35.8%","placeboRate":"","totalAtRisk":867,"totalAffected":310,"trialsReporting":3},{"effect":"CONSTIPATION","drugRate":"25.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":299,"trialsReporting":2},{"effect":"Neutrophil count decreased","drugRate":"33.3%","placeboRate":"","totalAtRisk":867,"totalAffected":289,"trialsReporting":3},{"effect":"ALOPECIA","drugRate":"23.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":270,"trialsReporting":2},{"effect":"ABDOMINAL PAIN","drugRate":"21.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":250,"trialsReporting":2},{"effect":"Paronychia","drugRate":"43.9%","placeboRate":"","totalAtRisk":497,"totalAffected":218,"trialsReporting":2},{"effect":"Vomiting","drugRate":"24.5%","placeboRate":"","totalAtRisk":867,"totalAffected":212,"trialsReporting":3},{"effect":"Constipation","drugRate":"24.3%","placeboRate":"","totalAtRisk":867,"totalAffected":211,"trialsReporting":3},{"effect":"ANAEMIA","drugRate":"17.8%","placeboRate":"","totalAtRisk":1175,"totalAffected":209,"trialsReporting":2},{"effect":"Dry skin","drugRate":"41.6%","placeboRate":"","totalAtRisk":497,"totalAffected":207,"trialsReporting":2},{"effect":"HYPOKALAEMIA","drugRate":"16.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":192,"trialsReporting":2},{"effect":"DRY SKIN","drugRate":"15.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":184,"trialsReporting":2},{"effect":"ASTHENIA","drugRate":"15.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":183,"trialsReporting":2},{"effect":"DYSGEUSIA","drugRate":"15.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":181,"trialsReporting":2},{"effect":"DERMATITIS ACNEIFORM","drugRate":"34.6%","placeboRate":"","totalAtRisk":518,"totalAffected":179,"trialsReporting":1},{"effect":"PYREXIA","drugRate":"14.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":171,"trialsReporting":2},{"effect":"INSOMNIA","drugRate":"14.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":171,"trialsReporting":2},{"effect":"STOMATITIS","drugRate":"33.0%","placeboRate":"","totalAtRisk":518,"totalAffected":171,"trialsReporting":1},{"effect":"EPISTAXIS","drugRate":"14.5%","placeboRate":"","totalAtRisk":1175,"totalAffected":170,"trialsReporting":2},{"effect":"WEIGHT DECREASED","drugRate":"32.0%","placeboRate":"","totalAtRisk":518,"totalAffected":166,"trialsReporting":1},{"effect":"Hypomagnesaemia","drugRate":"18.8%","placeboRate":"","totalAtRisk":867,"totalAffected":163,"trialsReporting":3},{"effect":"PRURITUS","drugRate":"13.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":161,"trialsReporting":2},{"effect":"Hypokalaemia","drugRate":"18.5%","placeboRate":"","totalAtRisk":867,"totalAffected":160,"trialsReporting":3},{"effect":"MUCOSAL INFLAMMATION","drugRate":"30.7%","placeboRate":"","totalAtRisk":518,"totalAffected":159,"trialsReporting":1},{"effect":"Anaemia","drugRate":"17.8%","placeboRate":"","totalAtRisk":867,"totalAffected":154,"trialsReporting":3},{"effect":"DEHYDRATION","drugRate":"13.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":153,"trialsReporting":2},{"effect":"HYPOMAGNESAEMIA","drugRate":"28.6%","placeboRate":"","totalAtRisk":518,"totalAffected":148,"trialsReporting":1},{"effect":"HEADACHE","drugRate":"12.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":141,"trialsReporting":2},{"effect":"DIZZINESS","drugRate":"12.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":141,"trialsReporting":2},{"effect":"DYSPNOEA","drugRate":"12.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":141,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"15.2%","placeboRate":"","totalAtRisk":867,"totalAffected":132,"trialsReporting":3},{"effect":"Asthenia","drugRate":"28.3%","placeboRate":"","totalAtRisk":463,"totalAffected":131,"trialsReporting":2},{"effect":"Neutropenia","drugRate":"27.9%","placeboRate":"","totalAtRisk":463,"totalAffected":129,"trialsReporting":2},{"effect":"Taste disorder","drugRate":"26.0%","placeboRate":"","totalAtRisk":497,"totalAffected":129,"trialsReporting":2},{"effect":"DYSPEPSIA","drugRate":"10.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":124,"trialsReporting":2},{"effect":"COUGH","drugRate":"10.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":121,"trialsReporting":2}]},"_chembl":null,"_fixedAt":"2026-03-30T11:31:45.516635","allNames":"leucovorin (lv)","_dailymed":null,"mechanism":{"target":"","drugClass":"Folate analog","explanation":"Leucovorin works by replenishing folate levels in normal cells, which can be depleted by certain chemotherapy drugs. This helps to reduce side effects without compromising the treatment's effectiveness against cancer cells.","oneSentence":"Leucovorin enhances the effects of certain chemotherapy drugs by protecting normal cells from damage while not protecting cancer cells."},"_scrapedAt":"2026-03-28T04:11:21.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:54:05.195733+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(968)"],"trialDetails":[{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT06131840","phase":"PHASE1","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-11-20","conditions":"Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms","enrollment":914},{"nctId":"NCT06731803","phase":"PHASE1, PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":"Esophagogastric Adenocarcinoma","enrollment":36},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07432568","phase":"PHASE2","title":"A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT05567835","phase":"PHASE2","title":"A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2024-03-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":3},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT07363408","phase":"PHASE1","title":"Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-21","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":30},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT04689347","phase":"PHASE1, PHASE2","title":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2021-01-01","conditions":"Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT05945901","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-14","conditions":"Colorectal Cancer","enrollment":669},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT01312857","phase":"PHASE2","title":"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-03-07","conditions":"Metastatic Colorectal Cancer","enrollment":75},{"nctId":"NCT05678257","phase":"PHASE2","title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-04-18","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma","enrollment":180},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT06887218","phase":"PHASE2","title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-08","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT07099794","phase":"PHASE2","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":90},{"nctId":"NCT07085273","phase":"PHASE2","title":"Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-08-15","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT07074353","phase":"PHASE3","title":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":360},{"nctId":"NCT05714553","phase":"PHASE1, PHASE2","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-03-08","conditions":"Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant","enrollment":19},{"nctId":"NCT07060014","phase":"PHASE1","title":"NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-07-18","conditions":"Advanced Small Intestine Cancer, Appendiceal Cancers","enrollment":22},{"nctId":"NCT07047560","phase":"PHASE2","title":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer (CRC)","enrollment":46},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT04901741","phase":"PHASE2","title":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"TME Pharma AG","startDate":"2026-01","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT07021950","phase":"PHASE2","title":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-10","conditions":"Colorectal Cancer, Ivonescimab","enrollment":130},{"nctId":"NCT04084496","phase":"PHASE2","title":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-09-01","conditions":"Pancreatic Cancer","enrollment":80},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT02138617","phase":"PHASE2","title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05-06","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT04796948","phase":"PHASE1","title":"A Study of Irinotecan Liposome in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-08","conditions":"Advanced Pancreatic Cancer","enrollment":41},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT04825288","phase":"PHASE1, PHASE2","title":"XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2021-05-27","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT01957735","phase":"PHASE1","title":"BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors","status":"COMPLETED","sponsor":"BPGbio","startDate":"2013-10","conditions":"Metastatic Cancer, Cancer, Solid Tumor","enrollment":97},{"nctId":"NCT06826092","phase":"PHASE2","title":"Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2022-10-31","conditions":"Progression-Free Survival","enrollment":110},{"nctId":"NCT01652196","phase":"PHASE2","title":"Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"John Hays","startDate":"2012-11-14","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon","enrollment":56},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT06643793","phase":"PHASE2","title":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-11-04","conditions":"Colorectal Neoplasms Malignant","enrollment":30},{"nctId":"NCT04513951","phase":"PHASE2","title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-04-01","conditions":"Metastatic Colorectal Cancer","enrollment":62},{"nctId":"NCT06700603","phase":"PHASE2","title":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-11-20","conditions":"Pancreatic Cancer","enrollment":48},{"nctId":"NCT06688240","phase":"","title":"A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)","status":"NOT_YET_RECRUITING","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2024-11","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT06684158","phase":"PHASE2","title":"Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-30","conditions":"GC/GEJC","enrollment":70},{"nctId":"NCT06389760","phase":"PHASE2","title":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10-18","conditions":"Pancreatic Cancer","enrollment":57},{"nctId":"NCT06184698","phase":"PHASE2","title":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":173},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT06079346","phase":"PHASE2, PHASE3","title":"A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Oncotelic Inc.","startDate":"2024-05-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":455},{"nctId":"NCT06475326","phase":"PHASE2","title":"Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-05","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT06501664","phase":"PHASE3","title":"Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-08-01","conditions":"Esophageal Cancer","enrollment":360},{"nctId":"NCT05009953","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT06387810","phase":"PHASE2","title":"Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-17","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":45},{"nctId":"NCT06467565","phase":"PHASE2","title":"NALIRIFOX as Induction Therapy in LAPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT05751850","phase":"PHASE3","title":"HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-06-13","conditions":"First-line Treatment of Advanced Pancreatic Cancer","enrollment":778},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT04371224","phase":"PHASE2","title":"NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-06-23","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT06370754","phase":"PHASE1, PHASE2","title":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-30","conditions":"Pancreatic Cancer","enrollment":117},{"nctId":"NCT06363552","phase":"PHASE2","title":"A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianshu Liu","startDate":"2024-05","conditions":"Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT06259058","phase":"PHASE1, PHASE2","title":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-04-01","conditions":"Pancreatic Cancer","enrollment":96},{"nctId":"NCT02102789","phase":"PHASE3","title":"A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Yuhong Li","startDate":"2014-03","conditions":"Metastatic Colorectal Cancer","enrollment":142},{"nctId":"NCT06282120","phase":"","title":"Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-01-01","conditions":"Metastatic Biliary Tract Cancer","enrollment":30},{"nctId":"NCT06217042","phase":"PHASE3","title":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-02-05","conditions":"Pancreatic Cancer","enrollment":524},{"nctId":"NCT06210360","phase":"PHASE2","title":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-02-01","conditions":"Pancreatic Cancer","enrollment":134},{"nctId":"NCT02037048","phase":"PHASE2","title":"FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-02-10","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia","enrollment":63},{"nctId":"NCT06172036","phase":"PHASE2","title":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer","enrollment":180},{"nctId":"NCT06153368","phase":"PHASE2","title":"Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-19","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT02394795","phase":"PHASE3","title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":823},{"nctId":"NCT03721653","phase":"PHASE2","title":"FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2018-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":218},{"nctId":"NCT01068327","phase":"PHASE1","title":"Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2007-11-05","conditions":"Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer","enrollment":46},{"nctId":"NCT05074589","phase":"PHASE3","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-01-25","conditions":"Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy","enrollment":298},{"nctId":"NCT00601198","phase":"PHASE2","title":"A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":4},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT00003298","phase":"PHASE2","title":"Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-06-01","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT00303628","phase":"PHASE3","title":"Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-05-11","conditions":"Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer","enrollment":355},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT00002525","phase":"PHASE3","title":"Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1993-10-01","conditions":"Colorectal Cancer","enrollment":859},{"nctId":"NCT02344810","phase":"PHASE1, PHASE2","title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2015-03-06","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":""},{"nctId":"NCT05251038","phase":"PHASE1, PHASE2","title":"Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer","status":"WITHDRAWN","sponsor":"Devalingam Mahalingam","startDate":"2022-09-13","conditions":"Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03279289","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2017-10-25","conditions":"Metastatic Colorectal Cancer","enrollment":170},{"nctId":"NCT02023593","phase":"PHASE2","title":"FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2012-03","conditions":"Advanced Esophageal Carcinoma","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":968,"recentPublications":[{"date":"2026 Mar 20","pmid":"41860175","title":"Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.","journal":"Japanese journal of clinical oncology"},{"date":"2026","pmid":"41411717","title":"Deoxyuridine as a surrogate marker of thymidylate synthase inhibition contributes to a multivariable model predicting 5-FU/LV response in metastatic colorectal cancer.","journal":"Cancer treatment and research communications"},{"date":"2025 Dec 10","pmid":"41187298","title":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"date":"2025 Oct","pmid":"41117518","title":"Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.","journal":"Cancer medicine"},{"date":"2025","pmid":"41034079","title":"[Reappraisal of high-dose methotrexate therapy].","journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Leucovorin (LV)","genericName":"leucovorin-lv","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":11,"withResults":5},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:54:05.195733+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}